Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $375K | $1.38M | $2.27M | $642K |
| Revenue growth | — | — | — | — | — | — | 268.0% | 64.2% | -71.7% |
| Operating income | -$4.54M | -$20.0M | -$33.6M | -$82.3M | -$107M | -$160M | -$172M | -$67.2M | -$50.5M |
| Operating margin | — | — | — | — | — | -42572.0% | -12448.0% | -2967.6% | -7860.0% |
| Net income | -$4.54M | -$19.3M | -$33.0M | -$82.2M | -$107M | -$166M | -$179M | -$59.6M | -$69.9M |
| Net margin | — | — | — | — | — | -44201.9% | -12974.9% | -2630.1% | -10887.4% |
| EPS (diluted) | -$0.47 | -$1.32 | -$2.02 | -$3.79 | -$4.05 | -$5.92 | -$98.33 | -$23.51 | -$5.73 |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.20M | -$13.5M | -$27.1M | -$66.3M | -$82.2M | -$135M | -$155M | -$72.0M | -$57.6M |
| Capital expenditures | — | $340K | $870K | $316K | $445K | $139K | $20.0K | $0.00 | $0.00 |
| Free cash flow | — | -$13.8M | -$28.0M | -$66.7M | -$82.6M | -$135M | -$155M | -$72.0M | -$57.6M |
| Share buybacks | — | — | — | $9.02M | — | — | — | — | — |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $887K | $42.6M | $32.4M | $213M | $233M | $194M | $65.2M | $29.9M | $28.4M |
| Total assets | $1.35M | $43.5M | $36.4M | $220M | $239M | $206M | $73.7M | $38.3M | $44.9M |
| Total liabilities | $2.34M | $4.66M | $9.50M | $13.2M | $17.8M | $129M | $130M | $131M | $140M |
| Long-term debt | — | — | — | — | — | $93.1M | $101M | $103M | $84.7M |
| Shareholders' equity | -$982K | $38.9M | $26.9M | $207M | $222M | $76.8M | -$56.5M | -$93.1M | -$95.5M |
| Retained earnings | -$4.45M | -$23.7M | -$56.7M | -$139M | -$246M | -$412M | -$591M | -$650M | -$720M |
| Shares (wtd avg diluted) | 9.91M | 15.7M | 18.1M | 21.7M | 26.4M | 28.0M | 1.82M | 2.54M | 12.2M |
Every figure is extracted from BioXcel Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.